Abstract
We investigated the possible association between susceptibility to systemic lupus erythematosus (SLE) and single-nucleotide polymorphisms located in the promoter region of the interleukin-6 gene (−174 G/C) in a sample of the Egyptian population and the contribution of this polymorphism in the clinical or immunological manifestation of the disease. Forty-two Egyptian patients with SLE and 40 unrelated healthy control volunteers were genotyped by polymerase chain reaction followed by visualization on 4% agarose gel electrophoresis on ultraviolet transilluminator to detect the genotype distribution and allelic frequencies of the polymorphisms. The homozygous GG genotypes was significantly increased in SLE patients compared to control group (p value = 0.04). On the other hand, the heterozygous G/C genotype was significantly elevated in the controls compared to SLE patients (p value = 0.01). The odds ratio value for G/G was 2.6 with a 95% CI from 1.1 to 6.7. As regard the association of clinical manifestations to the genotype frequency, we found a statistical significant increase in the frequency of GG genotype with chest disease, nephritis, and arthritis. From this study, we suggest that G carrier is more susceptible to develop SLE and that SNP may have a role in the pathogenesis of the disease and may be associated with some of its clinical manifestations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chen WF, Fischer M, Frank G, Zlotnik A (1989) Distinct patterns of lymphokine requirement for the proliferation of various subpopulations of activated thymocytes in a single cell assay. J Immunol 143:1598–1605
Chua K, Kee B, Tan S, Lian L (2009) Interleukin-6 promoter polymorphisms (−174 G/C) in Malaysian patients with systemic lupus erythematosus. Braz J Med Biol Res 42(6):551–555
Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, Kim SH, Park HS, Suh CH (2007) Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 27(5):461–466
Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S et al (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–1376
Hostmann A, Jacobi AM, Mei H, Hiepe F, Dörner T (2008) Peripheral B cell abnormalities and disease activity in systemiclupus erythematosus. Lupus 17(12):1064–1069
Huang CM, Huo AP, Tsai CH, Chen CL, Tsai FJ (2006) Lack of association of interleukin-6 and interleukin-8 gene polymorphisms in Chinese patients with systemic lupus erythematosus. J Clin Lab Anal 20:255–259
Inker-Israeli M, Deans R, Wallace D, Prehn J, Ozeri-Chen T, Klinenberg J (1999) Elevated levels of endogenous IL6 in systemic lupus erythrematosus. Aputative role in pathogenesis. J Immunol 147:117–123
Kanabrocki EL, Sothern RB, Messmore HL, Roitman-Johnson B, Mc-Cormick JB, Dawson S, Bremner FW, Third JL, Nemchausky BA, Shirazi P, Scheving LE (1999) Circadian interrelationships among levels of plasma fibrinogen, blood platelets, and serum interleukin 6. Clin Appl Thromb Hemost 5:37–42
Kanada N, Tsuchida T, Tamaki K (1997) Testosterone suppresses anti-DNA antibody production in peripheral bloodmononuclear cells from the patients with SLE. Arthritis Rheum 40:1703–1711
Katsiari C, Tsokos G (2006) Systemic lupus erythematosus: from disease pathogenesis to therapy. Drug Discov Today Dis Mech 3:185–192
Klashman D, Martin R, Martinez-Maza O, Stevens R (1991) In vitro regulation of B cell differentiation by IL-6 and CD33 in SLE B cell subpopulations and antigen-induced normal B cells. Arthritis Rheum 34:276–286
May LT, Santhanam U, Tatter SB, Bhardwaj N, Ghrayeb J, Sehgal PB (1988) Phosphorylation of secreted forms of human beta 2-interferon/hepatocyte stimulating factor/interleukin-6. Biochem Biophys Res Commun 152:1144–1150
Nagafuchi H, Suzuki N, Mizushima Y, Sakana T (1993) Constitutive expression of IL6 receptors and their role in the excessive B cell function in patients with SLE. J Immunol 151:6525–6543
Ray A, LaForge KS, Sehgal PB (1990) On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 10:5736–5746
Ripley BJ, Goncalves B, Isenberg DA, Latchman DS, Rahman A (2005) Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis 64:849–853
Schotte H, Schluter B, Rust S, Assmann G, Domschke W, Gaubitz M (2001) Interleukin-6 promoter polymorphism (−174 G/C) in Caucasian German patients with systemic lupus erythematosus. Rheumatology 40:393–400
Tan E, Cohen A, Freis J (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1277
Taylor KD, Paul-Labrador M, Fischel-Ghodsian N, Fraser PA, Klinenberg JR (1999) Association of IL-6 gene alleles with systemic lupus erythematosus (SLE) and with elevated IL-6expression. Genes Immun 1(1):45–52
Xing Z, Gauldie J, Cox G et al (1998) IL-6 an anti inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 10:311–320
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hamdy, E., Aleem Afify, R.A., Kamal, A. et al. IL-6 promoter polymorphism (−174G/C) and systemic lupus erythematosus. Comp Clin Pathol 21, 975–979 (2012). https://doi.org/10.1007/s00580-011-1211-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00580-011-1211-x